Reddit Posts
ARKK's Misfits - A Bet on the Comeback Kings:
Reflection of my top and worse performers: MELI, HIMS, CRSPR, BEAM and Intellia
Highly shorted biotech stocks like BEAM and DNA (Ginkgo Bioworks) getting squeezed right now
CRSPR, Intellia, Beam, Pacific Biosciences, Illumnia, Editas, Invitae... Will any of these companies be huge in the future?
Unsure why there 2 different tickers of the same stock on NASDAQ
I reviewed my past year's stock positions, and I have one general rule I'd like to throw out there for anyone willing to listenb
Base editing (BEAM) cures teenage girl's T-cell Acute Lymphoblastic Leukemia
My father in law put a quarter of my savings in to hype stock. I guess I’m just holding on at this point.
CRISPR DD that's not only lazy, but also manages to stack a few levels of uncertainly, meaning only a fool would give this any credence...
My portfolio is trash. Should I sell all of it?
Big Pharma destroying small cap Biotech SGMO
Where’s the volume for gene editing stocks (CRSP, EDIT, NTLA, BEAM, etc.)?
Pharma+Biotech Portfolio : What to keep, remove and add?
Beam Therapeutics Partners With Sana Biotechnology. $BEAM $SANA
BEEM - A play for Oct 15 (7.5M float with 38% Short Interest)
Short BEAM GLOBAL...NUMBER 5 MOST SHORTED STOCK IN THE MARKET...ONLY 7 MIL SHARES TO ACCOMPLISH.... PERFECT OPPORTUNITY
FATE Therapeutics and BEAM Therapeutics : stocks worth buying?
BEEM….BEAM GLOBAL….let’s send this to the moon. Not only is this a great company with a ton of upside, as they have a great product that is fast to install and self charges via solar power, but It’s got a free float under 8 million shares, and it’s being extremely heavily shorted. See pics below.
I think Oncology Stocks Are A Good Place To Look Right Now
$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR
$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR
NTLA, CRSP, EDIT, BEAM, VERV, ARKG likely to fly on Monday
NTLA, BEAM, CRSP, VERV, EDIT, and ARKG likely to fly on Monday
I guess I am in the yolo club . CRISPR is the culture for gene editing. BEAM and EDIT, Doing good so far.
CRSP vs EDIT vs BEAM -- which would you choose for a 5-year high risk investment?
CRSP vs EDIT vs BEAM -- which would you choose for a 5-year high risk investment?
CRSP vs EDIT vs BEAM -- which would you choose for a 5-year high risk investment?
Mentions
Went 5X long BEAM on etoro
god damnit BEAM, I hadn't finished buying you
❤️ skiddly skadool, LIQUIDATION BEAM ☄️
Everyone is so blinded by high tech. Why don’t I see any biotech tickers in the first hundred messages? There are so many small companies ready to blow, very hard to pick just one, but I’ll go with BEAM.
BEAM 2 dollars EOD???
AUR - leading AV (freight) solution. RKLB - becomes the leading space platform. Notable: BEAM (base editing; see baby KJ). CLPT (MRI guided neurosurgery).
Also long CYBN in addition to CRSP and BEAM. Probably going to index though going forward because it’s hard to pick winners!
If you are gambling that much money on a pre-clinical/pre-commercial biotech stock, do a deep dive on $TELO. Just $1000-$2000 invested into TELO stock could give you better returns than $26,500 in BEAM by 2028
I’m investing in a new stock called ROPE and BEAM, who’s with me?
Anyone know why $BEAM is down 7%?
Just bought 1500 shares of BEAM after hours on a 85k port.
I own a little BEAM. Their founder seems super smart when I listen to him on podcasts.
Gene Editing to the Moon CRSP NTLA BEAM
Yup tide is rising on gene editing. CRSP, BEAM, VRTX for the win
What ever happened to BEAM? Weren't we supposed to be beamed up to the moon or something?
Just in case anyone is following me- nothing interesting here for me. I still have: CHRS, ANAB, NUVB, AUTL,HRTX, SPRY, PHAT. Will buy back BEAM, it was a mistake to sell it.
I've been buying mostly 1/27 dated LEAPS on random buzzy stocks & selling up 25-30% in a month or so over & over again when they pop. LYFT today. NBIS, AVGO, RDDT, PSKY, BEAM, UUUU, etc... I probably could have let some run more, but I'm stacking little wins. Feels good.
Riding more of the $BEAM short squeeze / recovery in CRISPR stocks.
CRSP is probably my riskiest one. I do like the space of gene editing but many others like BEAM and NTLA also doing well. They have good cash reserves and good progress. But 2 major factors for me… 1. While treating sickle cell is great, not much scale. But their phase 1 CTX310 is looking promising and focuses on cardiovascular health which is huge. I believe gene therapy is at infancy still and promising. 2. Recently a board director just bought a massive $50M mid-July. Some secondary factors… they have good cash runway, great brand recognition and this admin may be more favorable to medical trials and innovation. Could also be an acquisition target if trials progress. I don’t expect much day-to-day but don’t want to miss trial progress news or even acquisition.
Surprised there isn't much talk on $BEAM. Squeeze is on.
$BEAM short squeeze kicking in. That is all.
I forgot to mention that now I'm in NUVB, ANAB, HRTX, HUMA, CHRS, STOK SPRY, PHAT and plan to enter BEAM
Thanks! This is great. What would you say would be a good reentry for BEAM?
BEAM from my portfolio is exploding right now
wtf is this BEAM beaming to the moooooon
One more thing...it looks like that there is small potential ahead. If we are not breaking today 20, I'll most definitely close the trade. Also I will open today PHAT,SPRY,BEAM
Should I yolo my 90 year old mothers savings into $CRSP $BEAM and $NTLA ?
Why are CRISPR stocks ($BEAM, $CRSP, $NTLA) so heavily shorted?
Kind of feel like BEAM is the better play right now
If you are looking for a serious answer, my money would be on one of the CRISPr gene-editing companies. EDIT, CRBU, BEAM, NTLX, CRSP. Some have already begun utilizing their sequencing to save lives. Others are beginning to patent additional sequencing. I think the BIG one will come when a company realizes how to edit agricultural genetic code to utilize less nutrients, and grow in harsher climates.
i bought BEAM, CRSP, MRNA, VERV and KODK 4 weeks ago now!
“CRISPR is the **Ctrl+X, Ctrl+V** for your genes. Cut out disease, paste in tendies. Long $CRSP $NTLA $BEAM. Biotech Jesus has entered the chat.” 🧬💥🚀
Not just $CRSP. Also $EDIT, $BEAM, and $NTLA. All of them are working on *in vivo* editing - the moment these companies figure out the protein vehicles for *in vivo*, we'll start watching them work on *in vitro*. Then all bets are off.
How much did you invest in BEAM
$BEAM \~ $0.007 sold $0.03-0.04 $PENDLE \~ $0.9 avg sold $3-4
It looks like a sleeper moon-shot because its lead in-vivo base-editing therapy, BEAM-302, has already shown in humans that a single 60 mg IV dose can flip more than 90 % of patients’ faulty alpha-1 antitrypsin (AAT) protein into the healthy form without serious side-effects, and the FDA just granted Orphan-Drug status—meaning tax credits, waived filing fees and seven years of market exclusivity if it’s approved. The company is now dosing an even higher 75 mg cohort and says a full data dump is coming at a big liver conference this November; if safety holds and AAT levels climb further, the agency is expected to let Beam jump straight into a single-arm pivotal study. Meanwhile Beam sits on $1.2 billion in cash (runway into 2028) yet its entire market cap is only ~$1.7 billion, so the market is valuing the whole base-editing pipeline at about half a billion dollars—pennies compared with the multi-billion potential of curing AATD and other diseases in the queue. Gene-editing peers like CRISPR Therapeutics skyrocketed once they crossed similar milestones, so a clean fall read-out could double or triple BEAM’s share price as investors rush to reprice the risk-adjusted value of a platform that now has real human proof of concept. (Obviously still high risk—do your own due diligence.)
I just put a quarter mil on BEAM haha easy money
Okay well BEAM is up 3.65% in pre-market at $**17.86**, down >30% YTD. Hoping there are no off target effects! The OP has announced the NEJM report on a dozen subreddits, I imagine, to drive investor interest.
See aboce; this is base editing, not CAS. BEAM
This is base editing, not CAS9; BEAM is the base editor, not EDIT
My ATH are coming. A little rebalance here a little rebalance there. I am not beating the S&P by 10% over the past 2 weeks. MSFT and PM are my big players but CAT NVDA TSM STZ CRSP BEAM making me cock strong
While the stories are sexy, these are still early stage tech companies burning ever increasing cash. Now they are not being helped with the background of Marks leaving the FDA and RFK jr putting them in a spotlight. CRSP's COO just left after announcing another weak Q. Revenues are declining and losses increased not just for last Q, but all of 2024. BEAM losses increased, and analysts just revised down their estimates again. That doesnt mean that everything in the group is being taken out and shot. Intercellular (ITCI) saw revenues increase by +50% to $199mm, and while still making a loss, that loss was cut in half. In the last month, ITCI was up about +2.5% while BEAM was down -21% As the environment is getting more chaotic, fundimentals are much more important, and demostrating real progress is paramount. A sexy story will only get you so far.
So Cathy bought BEAM eh? I'll have to look into this...
CRSP has a single approved product that absolutely can't scale for sickle cell and has been poorly subscribed. They also have a fast follower that can scale (enough for the rare disease space). Casgevy is not selling to expectations, but anyone who understands the Sickle Cell space should have known that Casgevy was a super limited technology with severe side effects. This was always going to be a drug that dozens to hundreds of people would get, not thousands. The point was to get something to market as quickly as possible and start to tackle the regulatory and manufacturing challenges ahead of their more accessible followers with 1000x better side effects. BEAM and NTLA have zero drugs approved by the FDA or by anyone else and any revenue you see is just incidental tiny bits here and there from IP licensing, milestone payments from collaborators, reselling assets and equipment that they no longer need. The way you're valuing them doesn't work when the future products that justify their valuation literally can't be sold until they get through cliincal trials.
CRSP ebit margin: -1250% NTLA ebit margin: -1248% BEAM ebit margins: -52% future looks grim
All of those companies are in the rare disease space and are not doing anything you mention in your post. CRISPR and all of its related techs occupy this incredible space in the public imagination, where we imagine a GATTACA-like genetically engineered future. The reality is that gene editing is an early and inefficient technology. Over the next 10-20 years, it is going to exist in the rare disease space (you could also do embryo editing but the taboo against this is extremely strong and there is no path to regulatory approval). If you want to understand these companies, you need to understand what they are actually doing. That being said, I think there is real value in this space. Genetic liver diseases are absolutely reachable and if we can solve delivery outside of the liver, the diseases that get cured might become a lot less “rare”. BEAM is reporting Phase 1 results this year for Beam-302. It’s an attempt to cure a deadly liver disease with hundreds of thousands of patients. It is still a “rare” disease, but if results look good (and again, liver editing is very doable at this point), expect the stock to move up quite a bit
People have been saying that since 2018, when I first bought it. The tech is very promising, but they really haven't lived up to the hype, IMO. That said I did buy 200 shares of NTLA recently. I might buy BEAM again too.
Yup I lost a lot of money on genomic stocks - CRSP, BEAM, NVTA
BEAM 
CRSP ARKG BEAM… biotech stocks are so back today
8:30 am - wake up, take a deep swig of BEAM to start the day. Refresh random stock picker to find out what today's play is 8:45 am - boof amphetamines to power me through the hours of 1 tick chart watching 9:00 am - the local loan shark stops by my tent, I tell that asshole I'll have his money soon enough 9:15 am - release freshwater crab from its cage for divination ritual, utilizing the Cameroonian practice of nggam I will decide on calls or puts 9:25 am - begin edging prior to market open 9:30 am - fully leveraged 0 DTE options on highly illiquid chains 9:45 am - Chivas Regal, Dunhills 10:00 am - hallucinogens in order to more effectively commune with market spirit 10:15 am - profuse sweating, freshwater crab confirms bearish crossover 10:30 am - puts showing a profit, spread is atrocious 10:45 am - naked TSLA calls severely underwater, margin called 11:00 am - prepare to move my tent in order to avoid percussive patella therapy from local unscrupulous loan provider 12:00 pm - power nap 3:00 pm - deploy emergency capital gained from returning bottles and cans Market close - all options expire worthless, delete app and apply fake mustache. Contact coyote to facilitate immediate crossing over the border
> The loss of public trust in U.S. institutions is well-chronicled, and for an example of its cost consider the national mini-panic over unidentified aerial objects. No one in America seems to believe what anyone in authority says about them, and unproven claims are filling the vacuum. > > Thousands of Americans who aren’t cranks have seen drones or what they think are drones overhead. New Jersey of all places is a hotbed of sightings, for reasons no one has been able to explain. But sightings have occurred across the Northeast, as well as in California. Military facilities and critical infrastructure sites seem to be targets, if the eyewitnesses are right. > > Yet no one in Washington seems to be able to convincingly explain the sightings. A joint statement Thursday by the FBI and Department of Homeland Security said: “We have no evidence at this time that the reported drone sightings pose a national security or public safety threat or have a foreign nexus.” > > The statement added that “Historically, we have experienced cases of mistaken identity, where reported drones are, in fact, manned aircraft or facilities. We are supporting local law enforcement in New Jersey with numerous detection methods but have not corroborated any of the reported visual sightings with electronic detection. To the contrary, upon review of available imagery, it appears that many of the reported sightings are actually manned aircraft, operating lawfully.” > > Yet the unexplained sightings persist. One caused Stewart International Airport in New York’s Hudson Valley to shut down its runways for an hour on Friday night. Gov. Kathy Hochul demanded answers from the Biden Administration. Former Maryland Gov. Larry Hogan, not known as a show-boater, says he saw a flurry of aerial objects above his home in Davidsonville, Md. > > Members of Congress are demanding answers or offering their own theories. Rep. Jeff Van Drew, a New Jersey Republican, thinks the drones may have come from an Iranian “mothership” off the coast. The Pentagon rejects the claim. > > Jon Bramnick, a GOP state Senator in New Jersey, told NewsNation that, “It must be something going on that they can’t tell us because they are so fearful of what the public’s gonna do when they hear what the drones are doing.” This is how deep the suspicion runs. > > And when that happens, conspiracy theories fill the air as much as drones do. One Twitter account with some 192,000 followers posted on X that “WE ARE F—. THE DRONES ARE PROJECT BLUE BEAM.” We admit to not being fluent on this theory, but apparently Project Blue Beam refers to a plan by governments and the military to stage celestial events as a pretext to impose authoritarian rule. Don’t beam us up, Scotty. > > We’d ignore this stuff, except millions of people might believe it. That’s the world we live in. And sorry to say, the reason isn’t merely the result of conspiracists or crackpots who will exploit doubt for attention. > > The Biden Administration has squandered its credibility to the point that it’s rational not to believe what it says. Remember the Chinese spy balloon that traveled across the continental U.S.? The Administration downplayed its importance while it was courting better relations with Beijing, only to shoot it down over the Atlantic Ocean. It also downplayed Rep. Mike Turner’s warning, based on solid intelligence, about the danger from a potential Russian nuclear blast in space. > > The Administration failed for months to be candid about its migrant flights from the border to the U.S. interior. And for months it covered up the truth about President Biden’s declining mental and physical fitness, only to have it exposed in a debate. The government’s attempt to censor alternative views about Covid shutdowns during the Trump Administration also spread mistrust. The more Americans don’t trust their government, the more panic or protests are possible. > > On Sunday New York Gov. Hochul said the feds are deploying high-tech detection gear to her state to help with the drone swarms. The feds need to explain to Congress and the public with more specificity what is really going on. But the larger need is for a government Americans can trust.
Got my bottle of BEAM by my side, ready to start trading complicated depreciating financial derivatives that have multiple volatile and interconnected moving parts that I don't understand 
Put that .02 in BEAM like never said and your back in business.
DRINKIN BEAM REASSURES ME THAT MY TECHNICAL ANALYSIS IS CORRECT 💯
just found this comment from 24 mins ago *"You’re not late. I put top 100 coins and also AI and gaming with will be the narrative this cycle (along with memes)* *This portfolio will realistically 5-10x by EOY 2025. The lower cap coins will 10-20x. Good luck. If you check, all of these except SOL are completely still down. You’re early. Another good play is $RIOT. Buy calls and print money. It’s going to 50$ for sure. Already made a million in RIOT and I’ll keep buying calls until it doesn’t work.* *$SOL $AVAX $LINK $WIF $FTM $RUNE $BEAM $GALA $PAAL $0x0 $SUPER* *You’re not late."* I shit you not you can probably find this exact comment word for word from 2021
You’re not late. I put top 100 coins and also AI and gaming with will be the narrative this cycle (along with memes) This portfolio will realistically 5-10x by EOY 2025. The lower cap coins will 10-20x. Good luck. If you check, all of these except SOL are completely still down. You’re early. Another good play is $RIOT. Buy calls and print money. It’s going to 50$ for sure. Already made a million in RIOT and I’ll keep buying calls until it doesn’t work. $SOL $AVAX $LINK $WIF $FTM $RUNE $BEAM $GALA $PAAL $0x0 $SUPER
BEAM and NTLA have really good pipelines too. Much easier plan imo
I mean... Your biggest worry should be that you could lose $100k overnight, not that you might have to be more conservative and therefore not retire quite as early! But anyways... Tell me why I should prepare myself to get hurt by CRSP again! I bought the absolute fucking TOP back in 2021 and got decimated. BEAM and EDIT also, so why do you like CRSP and not a gene etf and why now?
Several mid-cap stocks have started to bounce back, including **Madrigal Pharmaceuticals (MDGL)**, **CymaBay Therapeutics (CBAY)**, **Iovance Biotherapeutics (IOVA)**, and **Beam Therapeutics (BEAM)**, which have shown solid rebounds thanks to positive clinical trial results, strategic acquisitions, and broader improvements in biotech sentiment. It’s an exciting time for the sector, looking forward to hearing your thoughts as well! 
Everyone knows about Moderna. How is it under the radar? I prefer CRSP and BEAM for high risk high reward biotech.
Any of the in-vivo ones like NTLA and BEAM. Ex-vivo like CRSP is far too invasive, costs too much and can’t be scaled.
The whole gene editing industry hasn’t shown potential to make profits so it’s just being heavily shorted. Same for NTLA, BEAM, EDIT, VERV, etc.
I don’t think earnings will shit itself, but it’s possible. My bets more on their data release for BEAM 101 human trial before the end of the year. I believe BEAM 101 data will blow CRSP out of the water. Sickle Cell Disease will be a thing of the past. I believe base editing is superior to CRSPs method for sickle cell specifically. I like their Alpha 1 anti trypsin as well but not familiar with it. If earnings in a few days cause a dip, I will likely buy more.
No unaliving allowed. BEAM. Maybe wait for a dip. BEAM will trade over 40 easy by end of year.
[BEAM $80 target?](https://stocks.apple.com/A2LlXzIK_Szm6tgqGapfNiQ)
BEAM Therapeutics- Gene therapy is the next bull run and Beam is getting successful results plus saw a good volatility.
I’m in big on BEAM. After selling Tesla, this is my biggest position. I believe and stand by it. Currently on the pan 🤡
Bruh, that question is really simple. IT ALWAYS WAS. It's like a simple 2+2 math, now a harder question would be: Is gaming still a real investment in 2024? I honestly believe it is, I have a lot of faith in the games that are coming out and in the hubs that manage their communities like superverse or idk... chains like BEAM probably
Yup. I held for about 3 years and then realized losses across about 5 crisper gene therapy companies to reduce taxes on some profits I skimmed. And now I keep wondering whether I should buy back in. I def, 100% believe in growth and social transformation from gene therapy and related areas such as dna sequencing. But do I believe in the power of one (or a small number) of companies to realize profits from it? There I’m not so sure. Why did you choose CRSP? Why not BEAM? Why not EDIT? Why not NTLA? Why not companies with industry-focused applications (instead of medical) like DNA? Why not sequencing machines like PACB? I personally have never been in a biology lab to use crispr but people tell me it is a pretty straight forward, easy to use mechanism. Not much of a barrier there… Could be that the genomic revolution ends up being like the airline revolution - changed the world, for sure, but didn’t necessarily deliver value to investors.
NTLA I like more based on their latest two data readouts. One of those readouts is re-dosing, allowing dose to effect or reversing certain edits. They also have a more seasoned leadership team. BEAM is next-gen CRISP via base editing with strong proxy data that it is effective via VERV readouts (they license tech from BEAM). I think they'll surpass CRSP success - they just move glacially slow. If I had to rank them at risk alone, CRSP would be least risky given they have Casgevy (awaiting sales data). I simply think they also have limits on their KO abilities and I am not a big fan of their leadership team's inexperience.
Nice! I like NTLA and BEAM a bit more but I think CRSP is de-risked significantly with a large cash pile and no debt too!
BEAM/CRSP is the next. With AI help, I believe CRISPR tech will be curing many genetic diseases, starting with sickle cell.
Gene editing, e.g. $NTLA $CRSP $BEAM
I got $CRSP early, it went up a lot, then I got $NTLA, $EDIT and $BEAM thinking I'd cover the competing DNA-editors, then all three crashed horribly, worse than $CRSP and I sold them in 2023 at massive losses. Then $CRSP worked for sickle-cell anemia and shot up, the others following it up (without me), then all have drifted down, and this last month $CRSP is down worse than the others. I think $EDIT was the Asian guy quarrelling with $NTLA's Doudna and $CRSP's Frenchies. Which of these is most promising now? Or should we get a little of each? (a la Cathie) Or should we sell all and forget about DNA-editing? It does seem big in the future, long-term.
Between BEAM and NTLA. I’m pretty bullish on biotech and gene editing.
The whole genomic sector is, check the state of BEAM CRSP ARKG etc These type of names trade well in a lower rate environment. Wednesdays news could be a huge catalyst for the sector.
Yes. This is a long term hold. I'm talking 10+ years. By my own analysis. Fair value is 4.94 assuming that production starts next year. So if 4.94 is the price just before production, stock is undervalued. Other commenter said everyone's doing lithium production but I find that the price of lithium is still high and higher than the lithium prices that LAC uses in their estimates and what I used for calculating fair value. Because the hold is long term, you should be investing at least 3,000 for it to be worthwhile. Anything less is a arguably not being allocated optimally (i.e. something like DQ offers lower risk and higher short term reward). Really is a buy and forget. The biggest difference between lac and other small caps is that with lac revenue is guaranteed. They already have the rights to the resource. It's not even worth $1B which is wild. Unless lithium futures are trading at pre 2019 levels, then I don't really see this stock being a loser. The reduction in share price so warranted. shareholders have expected rates of return and when they aren't seeing it they get impatient and want to cut the opportunity cost loss. Since different investors have different levels of patience it takes quite some time as we've seen for the stock price to correct. As long as you buy below fair value, you are safe in the long run. Stocks I did not buy below fair value: ABBV, HD, CP.TO, INTC (LOL), CMCSA, BEAM. It's unfortunate that many of these are blue chips as I had low expectations on Intel and beam but on Comcast I completely missed the fact that they carried a lot of debt so I didn't get to exit fast enough. Not really sure when to sell CMCSA but my notes says to sell it to buy lac and I've been rewarded for waiting so long.
CAVA earnings maybe. CRSP BEAM and other gene editing stocks might be good (there’s a cell therapy/gene editing conference starting today). BA and CVNA calls look good. And ofc SPY 0dtes but will probably be sideways
CRSP isn't really a gamble anymore in my opinion as a former junior geneticist turned physician; gene therapies will be huge; How huge and when and are they 'overvalued' currently is the big gamble as you allude to. generally it feels like we're in a dot-com bubble for gene editing; but picking long term winners between BEAM, DITAS, CRSP; etc can be a little tricky; especially in a rising rate environment for companies that has minimal real revenue. CRSP seems to bounce from lows of 40s and I expect it to go down more currently but likely around $50 I'm a slow buyer/DCA into it for long term benefit (5-10+ yr horizon).
Crispr stocks: NTLA, EDIT, CRSP, BEAM, CRBU (maybe wait for a bit more drop on this one), also RIVN
if you want a non-regarded long-term play for your retirement account to never look at, buy $BEAM and $PRME (sell long dated puts or buy 2025+ LEAPS). BEAM -- CRISPR 2.0 (ultra-precise gene-editing, think designer babies but we gotta cure diseases first. already capital-backed by google ventures, eli lilly, and more) PRME -- CRISPR 2.5 (even more precise adjunct to CRISPR). licensing deal with BEAM both at relative dumpy lows. eat 'em up, boys
This. The data is good, but people don't realize it yet. Especially the in-vivo stuff from NTLA/BEAM. I bought CRSP only when it went to $40 since it was a bargain and sold at $65, but the ex-vivo stuff is too expensive to do large scale so it's too risky for me. I don't think it will top 90 again. NTLA under $30 is a bargain right now. By summer, it's likely going to be high 30s / low 40s.
NTLA, crispr and their rivals BEAM all should be going up in next 2-3 years atleast.